[A case of recurrent advanced gastric cancer suggesting the efficacy of TS-1 and CDDP combination chemotherapy].

Abstract

The patient, a 53-year-old male, underwent radical surgery for advanced gastric cancer (stage IV). On the second day after surgery, adjuvant chemotherapy consisting of 250 mg/day 5-FU (i.v.) for 14 days, followed by 450 mg/day of UFT-E for about 12 months, was initiated. About 21 months after surgery (7 months after cessation of medication), the CA19-9 level had risen (136 U/ml). After 26 months, the patient experienced a backache and his CEA and CA19-9 levels had risen 11.7 ng/ml and 869 U/ml, respectively. The results from an imaging examination were suggestive of multiple bone metastases and para-aortic lymphatic metastasis. Chemotherapy was resumed with only TS-1 (100 mg/day). Because the tumor markers (TM) continued to rise, he was hospitalized and the medication was combined with daily administration of 10 mg of CDDP (TS-1 + CDDP protocol). When the total dose of CDDP reached 160 mg, there was a dramatic drop in the TM (surrogate marker) level. The patient was discharged and medication of TS-1 and 10 mg/day of CDDP twice a week was continued on an outpatient basis. Five months after the initial administration of FP, the CEA and CA19-9 returned to normal levels (4.3 ng/ml and 33 U/ml, respectively). Metastases to the para-aortic lymph nodes had disappeared and the sites of bone metastases were reduced in size. The patient was able to resume his full social activities. Since that time, a second-line therapy has been added. Currently (about two years after the recurrence), he is still undergoing therapy with TS-1 + CDDP.

• Authors: Yoichiro Uchida, Ryusuke Denno, Kazutaka Obama, Koichi Kinoshita, Michiyuki Kanai, Arimichi Takabayashi
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 29 Issue 11 Pg. 1995-9 (Nov 2002) ISSN: 0385-0684 [Print] Japan
• PMID: 12465403 (Publication Type: Case Reports, English Abstract, Journal Article)

Chemical References

• Drug Combinations
• Pyridines
• S 1 (combination)
• Tegafur
• Oxonic Acid
• Cisplatin

Topics

• Adenocarcinoma (drug therapy, secondary, surgery)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Aorta
• Bone Neoplasms (secondary)
• Chemotherapy, Adjuvant
• Cisplatin (administration & dosage)
• Drug Combinations
• Humans
• Lymph Nodes (pathology)
• Lymphatic Metastasis
• Male
• Middle Aged
• Oxonic Acid (administration & dosage)
• Pyridines (administration & dosage)
• Remission Induction
• Stomach Neoplasms (drug therapy, pathology, surgery)
• Survivors
• Tegafur (administration & dosage)